Asian Journal of Psychiatry
Volume 2, Issue 3 , Pages 106-111 , October 2009

Changes in metabolic syndrome parameters in patients with schizoaffective disorder who participated in a randomized, placebo-controlled trial of topiramate

  • Ranita Basu

      Affiliations

    • Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O’Hara Street, Pittsburgh, PA 15213-2593, USA
    • Veterans Administration Health System, Highland Drive, Pittsburgh, PA, USA
    • ,
  • T.G. Thimmaiah

      Affiliations

    • Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O’Hara Street, Pittsburgh, PA 15213-2593, USA
    • Fairview Hospital, Cleveland, OH, USA
    • ,
  • Jatinder M. Chawla

      Affiliations

    • Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O’Hara Street, Pittsburgh, PA 15213-2593, USA
    • SUNY Downstate Medical Center, Brooklyn, NY, USA
    • ,
  • Patricia Schlicht

      Affiliations

    • Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O’Hara Street, Pittsburgh, PA 15213-2593, USA
    • ,
  • Andrea Fagiolini

      Affiliations

    • University of Siena, Department of Neuroscience, Siena, Italy
    • ,
  • Jaspreet S. Brar

      Affiliations

    • Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O’Hara Street, Pittsburgh, PA 15213-2593, USA
    • ,
  • Shakeel Ahmed Khan

      Affiliations

    • Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O’Hara Street, Pittsburgh, PA 15213-2593, USA
    • ,
  • Anuradha Challa

      Affiliations

    • Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O’Hara Street, Pittsburgh, PA 15213-2593, USA
    • Michigan State University, Department of Psychiatry, East Lansing, MI, USA
    • ,
  • K.N. Roy Chengappa

      Affiliations

    • Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O’Hara Street, Pittsburgh, PA 15213-2593, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 412 246 5006; fax: +1 412 246 5007.

References 

  1. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366(9491):1059–1062
  2. Balkau B, Deanfield JE, Després JP, Bassand JP, Fox KA, Smith SC, et al. International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation. 2007;116(17):1942–1951
  3. Basu R, Brar JS, Chengappa KN, John V, Parepally H, Gershon S, et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder–bipolar subtype. Bipolar Disorders. 2004;6(4):314–318
  4. Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry. 2005;66(2):205–212
  5. Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obesity Research. 2003;11(6):722–733
  6. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301(20):2129–2140
  7. Chengappa KNR, Kupfer DJ, Parapelly H, et al. A placebo-controlled, random-assignment parallel group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Bipolar Disorders. 2007;9:609–617
  8. Chengappa KNR, Levine J, Rathone D, Parepally H, Atzert R. Long term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case series. European Psychiatry. 2001;(16):186–190
  9. Egger C, Muehlbacher M, Schatz M, Nickel M. Influence of topiramate on olanzapine-related weight gain in women: an 18-month follow-up observation. Journal of Clinical Psychopharmacology. 2007;27(5):475–478
  10. Enas EA, Mohan V, Deepa M, Farooq S, Pazhoor S, Chennikkara H. The metabolic syndrome and dyslipidemia among Asian Indians: a population with high rates of diabetes and premature coronary artery disease. Journal of the CardioMetabolic Syndrome. 2007;2(4):267–275
  11. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  12. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disorders. 2005;7(5):424–430
  13. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–359
  14. Ganguli R. Behavioral therapy for weight loss in patients with schizophrenia. Journal of Clinical Psychiatry. 2007;68(Suppl. 4):19–25
  15. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–2752
  16. Gupta M, Singh N, Verma S. South Asians and cardiovascular risk: what clinicians should know. Circulation. 2006;113(25):e924–e929
  17. Gupta S, Masand PS, Virk S, Schwartz T, Hameed A, Frank BL, et al. Weight decline in patients switching from olanzapine to quetiapine. Schizophrenia Research. 2004;70(1):57–62
  18. Guy . Clinical Global Impressions. New Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. Rockville, MD: US National Institutes of Mental Health; 1976;pp. 218–222
  19. Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. Journal of Clinical Psychiatry. 2003;64(5):575–579
  20. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987;13(2):261–276
  21. Levine J, Chengappa KNR, Patel A, Vagnucci A, John V, Brar JS, et al. Obesity and medical illness in psychiatric patients admitted to a long-term psychiatric facility. Journal of Psychiatric Practice. 2001;7:432–439
  22. Liang Y, Chen X, Osborne M, DeCarlo S, Jetton TL, Demarest K. Topiramate ameliorates hyperglycemia and improves glucose-stimulated insulin release in ZdF rats and db/db mice. Diabetes, Obesity and Metabolism. 2004;7(4):360–369
  23. McElroy SL, Frye MA, Altshuler LL, Suppes T, Hellemann G, Black D, et al. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disorders. 2007;(4):426–434
  24. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research. 2005;80(1):19–32
  25. Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clinical Therapeutics. 2005;27(12):1930–1941
  26. Misra, R., Patel, T., Kotha, P., Raji, A., Ganda, O., Banerji, M., Shah, V., Vijay, K., Mudaliar, S., Iyer, D., Balasubramanyam, A. Prevalence of diabetes, metabolic syndrome, and cardiovascular risk factors in US Asian Indians: results from a national study. Journal of Diabetes and its Complications. doi:10.1016/j.jdiacomp.2009.01.003.
  27. Montes JM, Rodriguez JL, Balbo E, Sopelana P, Martin E, Soto JA, et al. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2007;31(2):383–388
  28. Pan WH, Yeh WT, Weng LC. Epidemiology of metabolic syndrome in Asia. Asia Pacific Journal of Clinical Nutrition. 2008;17(Suppl. 1):37–42(Review)
  29. Ryback R, Bfodsky L, Littman R. Topiramate as an adjunctive treatment in psychiatric patients with diabetes. Primary Psychiatry. 2005;12:57–60
  30. Tan CE, Ma s, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the Metabolic syndrome to Asians?. Diabetes Care. 2004;27:1182–1186
  31. Tonstad S, Tykarski A, Weissgarten J, Ivleva A, Levy B, Kumar A, et al. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. American Journal of Cardiology. 2005;96(2):243–251
  32. Toplak H, Hamann A, Moore R, Masson E, Gorska M, Vercruysse F, et al. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. International Journal of Obesity. 2007;31(1):138–146
  33. WHO expert consultation . Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;157–163
  34. WHO/IASO/IOTF, 2000. The Asia-Pacific perspective: redefining obesity and its treatment. Full document available http://www.idi.org.au/obesity_report.htm (accessed 02.27.2009).
  35. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M, Group O-S. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity. 2004;28(11):1399–1410
  36. Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008;299(2):185–193

PII: S1876-2018(09)00063-X

doi: 10.1016/j.ajp.2009.08.006

Asian Journal of Psychiatry
Volume 2, Issue 3 , Pages 106-111 , October 2009

Article Tools